Newtown, PA, United States
Newtown, PA, United States

BioClinica, Inc., formerly Bio-Imaging Technologies, Inc., founded in 1990, is a Pennsylvania-based company that supports pharmaceutical and medical device innovation.BioClinica’s initial service was medical imaging for clinical trials. It is used to capture, collect, control quality, provide blinded reading services to the final delivery to the sponsor company and to the FDA or EMEA if required for medical images in a wide range of imaging modalities. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

News Article | May 18, 2017
Site: www.prnewswire.com

Claudine brings to Greenphire a unique blend of experience derived from prior leadership roles with large global enterprises such as General Electric and Dell Computer as well as smaller eClinical organizations like BioClinica and CRF Health. Throughout her career, Claudine has demonstrated an exceptional ability to drive operational excellence in dynamic and rapidly scaling environments. "Greenphire's solutions impact the entire clinical trial ecosystem – from the patient through the study sponsor. Building a team of trusted experts in clinical trial payment automation is critical," commented Claudine. "I am excited to have the opportunity to apply my years of experience at an organization with such a vibrant and dynamic organization that is leading an industry transformation." About Greenphire Greenphire is the global leader in clinical trial payment automation. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more complete financial data, resulting in better trials. Learn more at www.greenphire.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/greenphire-appoints-claudine-paccio-as-chief-operations-officer-300460037.html


News Article | May 4, 2017
Site: www.prnewswire.com

NEW YORK, May 4, 2017 /PRNewswire/ -- According to Stratistics MRC, the Global Electronic Data Capture (EDC) market is accounted for $XX million in 2016 and is expected to reach $XX million by 2022 growing at a CAGR of XX% from 2016 to 2022. Read the full report: http://www.reportlinker.com/p04823112/Electronic-Data-Capture-EDC-Systems-Global-Market-Outlook.html Factors such as improvements in the information management and analysis, increasing product pipeline, improved compilation of technical & scientific data, increasing outsourcing by pharmaceutical and biotechnological companies and demand from EDC services are contributing towards market growth. Growing adoption of cloud-based services by manufacturers and installation of fully integrated services will provide lucrative opportunity for the market growth. However, lack of skilled research professionals is restraining the market growth. Services segment is leading the market because of large number of Contract Research Organizations (CROs) presence. The web-based delivery mode is anticipated to be the largest market share owing to acceptance of inexpensive information management in clinical trials. In the development phase segment, Phase I is estimated to grow at a significant rate because of direct data and remote information capturing as well as rising R&D expenditure on the development of novel drugs . CROs is projected to be the largest market as the majority of them use commercially developed enterprise applications to support clinical development in phase II and phase III trials. North America is the leading market due to presence of major pharmaceutical companies. Asia Pacific is anticipated to be the fastest growing market because many pharmaceutical companies are using eClinical solutions. Some of the key players in global Electronic Data Capture (EDC) market are BioClinica,Clinical CLINIPACE, INC.,DATATRAK International, Inc., Medidata Solution, Inc, Merge Healthcare Incorporated, Omni Comm Systems, Inc., Openclinica, LLC, Oracle Corporation and PAREXEL International Corporation. Delivery Modes Covered: - Cloud-Based - Licensed Enterprise - Web Based Development Phases Covered: - Phase I - Phase II - Phase III - Phase IV Applications Covered: - Academic Institutes - Pharma & Biotech Organizations - CROs - Hospitals - Medical Device Manufacturers Components Covered: - Services - Software Regions Covered: - North America o US o Canada o Mexico - Europe o Germany o France o Italy o UK o Spain o Rest of Europe - Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific - Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Read the full report: http://www.reportlinker.com/p04823112/Electronic-Data-Capture-EDC-Systems-Global-Market-Outlook.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/electronic-data-capture-edc-systems---global-market-outlook-2016-2022-300451981.html


News Article | July 17, 2017
Site: www.prweb.com

Bioclinica®, a leading provider of technology-enabled clinical trial solutions, today announced safety software company AB Cube has joined its eHealth App xChange™, an alliance channel within the eHealth Solutions business segment to advance technology innovation across life sciences and healthcare. Under the partnership, AB Cube’s comprehensive, cloud-based pharmacovigilance platform for management of adverse events will become part of Bioclinica’s extensive eHealth App xChange offerings available in the Bioclinica eHealth Cloud™. “Our eHealth Solutions team is collaborating with highly innovative technology partners around the globe, and in AB Cube we foresee an industry transformation toward a next-generation safety platform that brings simplicity, proven savings and efficiencies with a unique cloud architecture and advanced process automation capabilities,” said Bioclinica President eHealth Solutions Mukhtar Ahmed. Paris-based AB Cube’s safety technology, already selected by more than 300 companies worldwide as their safety platform of choice, has the flexibility to handle any volume of case processing, large or small. Pharmacovigilance, crucial to an effective drug regulation system and clinical research, is focused on evaluating and monitoring adverse drug reactions and minimizing the risk of harm to patients. The Bioclinica-AB Cube collaboration brings a cloud safety platform along with process automation capabilities to simplify the PV process and maintain compliance with strict worldwide laws, regulations and guidance. “We are delighted to partner with Bioclinica on a safety solution that aligns so well with their technology-agnostic philosophy,” said AB Cube CEO Matthieu Doresse. “As a true SaaS offering where everyone uses the same version and is informed well in advance of automatic system updates, the platform is a huge leap forward in terms of ease of implementation and maintenance as well as decreased total cost of ownership.” Additionally, the software easily scales up or down dependent on an organization’s needs, circumstances, case processing volume fluctuations and other variables that otherwise would be costly and difficult to manage. AB Cube’s safety system is available with optional hosting, support and professional consulting services provided by Bioclinica, such as business process and change management. This allows organizations to tap the extensive expertise, resources and experience within Bioclinica’s industry-leading Safety & Regulatory Solutions division, including first and second level help desk. The specialized team ─ comprising more than 1,000 Healthcare Professionals and technology specialists worldwide with extensive domain expertise across all vigilance and regulatory compliance aspects ─ offers a full spectrum of PV services supporting safety. Customers using AB Cube’s solutions can employ Bioclinica’s end-to-end Pharmacovigilance as a Service (PVaaS) model where Bioclinica is responsible for management of underlying applications and infrastructure. Additionally Bioclinica may tackle the case processing, performed by drug safety specialists experienced in handling more than 700,000 Individual Case Safety Report (ICSR) cases annually for customers operating on a variety of PV systems. “No matter the technology currently in place, PVaaS is a great alternative for companies seeking to outsource safety infrastructure, resources and case processing to dedicated safety and regulatory experts in a proven, cost-effective model,” Ahmed commented. “We welcome discussions to assist organizations in achieving their safety needs with a streamlined system and supporting services for efficiency, quality and cost benefits.” Bioclinica’s expansion of partners within its App xChange is part of a continuum in the eHealth Solutions business segment to make it easier for regulated industries to access best-available technology and services while also helping organizations evolve to keep pace with change. To learn more about Bioclinica, eHealth Solutions, App xChange and its many innovative partners, visit http://www.Bioclinica.com . Get clinical trial insights in the Bioclinica blog and the latest Company news on Bioclinica LinkedIn and Twitter channels. About AB Cube Founded in 2006, AB Cube offers software for pharmacovigilance, medical device vigilance, cosmetovigilance, biovigilance and veterinary pharmacovigilance. AB Cube’s SafetyEasy™ is designed to be easy and user friendly, reliable and secure. With over 300 companies and more than 1,800 unique users, AB Cube’s customers include MAH, biotech, CRO, CSO, as well as institutional and commercial developers. Learn more about AB Cube at http://www.AB-Cube.com. About Bioclinica Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging & Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Randomization & Trial Supply Management; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of investigative sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices and research sites in the U.S., Europe, Asia, and Latin America. Learn more at http://www.bioclinica.com.


News Article | May 31, 2017
Site: www.prweb.com

Bioclinica® Financial Lifecycle Solutions (FLS), a division of eHealth Solutions, which pioneered fit-for-purpose financial automation tools in the pharmaceutical sector, today announces the release of the industry’s first complete clinical financial lifecycle platform with ClinPay® for seamless global site payment automation coupled with trial budgeting and forecasting capabilities in the latest release of ClinPlan®, 2.0. “By using ClinPlan and ClinPay, two best-in-class FLS solutions, our customers have end-to-end visibility, control and efficiency across their global site payments process along with trial budgeting and forecasting and site contracts,” said Bioclinica Senior Vice President and FLS General Manager Bob Gabriel. The Bioclinica FLS platform is the industry’s only financial software solution that delivers financial budgeting and forecasting capability enterprise-wide and provides uninterrupted insights from forecast to final payment. ClinPay automation empowers the user to issue global investigator payments quickly and accurately, while providing transparency into payments for increased site satisfaction. ClinPlan addresses the major challenge of grants forecasting by accounting for actual trial costs over the course of a trial for substantially increased budget accuracy. In addition to enabling organizations to continually update and reforecast clinical trial budgets based on trial cost actuals, ClinPlan 2.0 applies intelligent modeling algorithms to real-time site payment data from ClinPay for accurate mapping of actuals to detailed assumptions in the latest budget forecast. The ability to reforecast based on actuals as a trial progresses solves the problem of increasingly outdated original forecasts, thereby significantly decreasing budget variance while sharply reducing time-consuming and resource-intensive effort common with manual and other forecasting methods. What’s more, Bioclinica FLS technology is vendor-agnostic, featuring pre-built integrations with all leading EDC systems in use today. This is an important consideration for CROs that serve multiple sponsors on different EDC systems, necessitating a scalable solution that can be implemented quickly and easily. “ClinPlan 2.0 is another example of how Bioclinica Financial Lifecycle Solutions is delivering tangible technology innovation to the pharmaceutical industry to help solve the most pressing financial management challenges in clinical research,” noted Gabriel. “Now, companies can not only rapidly reforecast budgets based on the latest trial payments information, but also use Bioclinica’s end-to-end financial lifecycle platform to promptly identify and correct problem areas such as overpayments, cash management and compliance.” Industry professionals can see FLS product demonstrations in booth 1027 during DIA on June 18-22 in Chicago where Bioclinica is exhibiting and showcasing eHealth Solutions. Watch the FLS product video here. Learn more about Bioclinica Financial Lifecycle Solutions in the Bioclinica blog and on Bioclinica LinkedIn and Twitter channels. About Bioclinica Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.


News Article | June 2, 2017
Site: www.prweb.com

Bioclinica®, the worldwide leader in science-enabled medical imaging and core lab service supporting clinical development, today announces the formation of a dedicated team focused on Oncology rescue studies. The team comprises specialists with scientific, medical, Oncology and related domain expertise, as well as senior project managers and operational leads experienced in Oncology rescue studies. “Due to their large-scale, global nature, Oncology trials tend to be difficult to manage,” said Bioclinica’s Medical Imaging & Biomarkers Chief Operating Officer Andrew Kraus. Compounding this, differences in type, location and progression of tumors require complex assessment criteria. “To combat these challenges and to address critical worldwide logistics needed for success, Bioclinica partners with sponsors to remove roadblocks to new Oncology therapies.” Bioclinica has more than 1,100 Oncology trials in its portfolio, including 64 U.S. FDA-approved Oncology therapies. The team has provided imaging core lab, expert independent review and supporting scientific services to sponsors from top tier pharmaceutical to smaller companies since 1990. Today Bioclinica is the leading imaging provider in the life sciences industry, offering comprehensive support in all trial phases for all major indications. In recent years Bioclinica has been tapped to correct a variety of problems in Oncology studies including data loss from scans unable to be analyzed due to lax imaging quality standards on the part of inexperienced providers and those for whom imaging is not a core service. “It’s something we avoid in our own studies by having stringent quality control and imaging standards to ensure data across all imaging modalities are acquired in accordance with the protocol and consistent across all time points, subjects and sites,” Kraus explained. Aside from its imaging expertise, Bioclinica systems, infrastructure and proactive site management approach are credited by Kraus as key to obtaining the best quality imaging scans possible. Bioclinica has successfully recovered 14 trials in just the past three years. In one study the sponsor was nearing database lock when they discovered their imaging provider was unable to deliver readings in time. Bioclinica helped the sponsor get out of an urgent situation so they could make their regulatory submission. Other issues such as variability in analysis can be avoided by having standardized imaging in place across all subjects and qualified, experienced reader management. As imaging is a core specialty of Bioclinica, it has scale and dedicated, in-house readers ─ the most experienced in the industry. Medical Imaging has approximately 600 employees across its global and growing organization with a staff that includes radiologists, oncologists, data managers, technologists and project managers. The team has unmatched regulatory experience, medical leadership, operational excellence, and a large global workforce to meet the most challenging demands of today’s Oncology trials. “Our team understands the crucial operational aspects and what it takes to run a successful Oncology trial,” Kraus commented. He added, “When Bioclinica steps into recovery mode, we do so with three decades of experience and a proven Rescue Study Plan of Action behind us. We work in close partnership with the sponsor to steer troubled studies back on course, paving the way to new Oncology therapies.” Industry professionals can meet with members of Bioclinica’s Oncology rescue team at ASCO in booth 13099 through June 5 where Bioclinica is exhibiting and showcasing its Imaging Oncology services. Learn more about Bioclinica’s Medical Imaging & Biomarkers business segment online, in the Bioclinica blog and on Bioclinica LinkedIn and Twitter channels. About Bioclinica Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.


News Article | May 23, 2017
Site: www.prnewswire.com

"MedNet's people and product make this a compelling offering in a commoditized market," remarked Murg. "iMedNet is an agile, efficient, and effective eClinical solution; the product architecture and feature set are fantastic and with a few tweaks, we can dominate the life sciences market." Prior to joining MedNet, Rich spent 11 years as Vice President of Sales for BioClinica where he helped grow a startup division to over $60M in annual revenue. Prior to representing software companies, he held several positions in Finance, working at companies such as FileNet and Disney. Richard holds a Bachelor of Science from the United States Military Academy and a Master of Business Administration from the University of Texas at El Paso. Richard was an officer in the United States Army and is a combat veteran. For more about iMedNet, or to schedule an iMedNet demonstration, please contact MedNet Solutions by email (contact@mednetstudy.com), by phone (866-258-2735) or by visiting MedNet's website. MedNet Solutions is a leading healthcare technology company specializing in electronic data solutions designed for the global life sciences community. MedNet's proven, flexible and easy-to-use cloud-based eClinical systems dramatically improve the efficiency of clinical studies and registries of all types and sizes. Beyond simply electronic data capture (EDC), MedNet's solutions deliver the tools and dashboards required to expertly manage all aspects of clinical research. Since 2001, pharmaceutical, medical device, biotechnology and Contract Research Organizations (CROs) around the world have trusted MedNet to consistently deliver the technology innovation, experience and reliability they need for success. For more information, please visit www.mednetstudy.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mednet-appoints-richard-murg-as-chief-revenue-officer-300462431.html


News Article | June 19, 2017
Site: www.prweb.com

Bioclinica® eHealth Solutions, which provides an agile ecosystem and domain expertise for sponsors and CROs to speed clinical development, announces the launch of Clean Patient Optics™, a first-of-its kind, fully-validated clinical trial software solution that surfaces insights to patient data for accelerated database lock and clinical trial timelines. The innovative product provides uninterrupted visibility into patient data status at the study, site and patient level, empowering study teams to optimally focus the data cleaning process and remove obstacles that can create costly delays. “Achieving database lock on time can be difficult, especially in larger trials with a vast amount of data to review and reconcile,” says Bioclinica’s eHealth Solutions Chief Technical Officer Andrew Masters. Clean Patient Optics is a technology-enabled solution for faster, easier and more efficient data cleaning and reconciliation. “Users apply insights to focus data cleaning, allowing the study team to meet or beat the database lock goal by days or even weeks.” Moreover, Clean Patient Optics serves as an early warning system, signaling if a vendor is behind on making updates, or if a site is slow in reporting SAE information to the pharmacovigilance team. With powerful data visualization tools at their fingertips, study teams can uncover patterns and observations about the status of patient data external to the EDC system, such as ECG, Central Safety Lab and other important data requiring reconciliation, helping avoid surprises at the end of a study. The entire study team benefits from Clean Patient Optics. Executive level personnel get answers about overall study health and team progress toward the database lock goal. Study managers, data managers and monitors see at a glance if a patient has reached the end of the study and any remaining data activities. They can quickly spot missing information, items to be reconciled, terms to be medically coded and pages to be source document verified. The benefits of implementing Clean Patient Optics for visibility into patient data cleaning include: Clean Patient Optics is readily implemented as a companion product to Bioclinica’s best-in-class Express® Electronic Data Capture (EDC) system and Data Management services ─ the enterprise solution of choice for world-leading pharmaceutical companies and CROs. “Our seamless solution provides sponsors and CROs unmatched capability to understand study health for accelerated clinical trial timelines,” Masters comments. Clean Patient Optics is another example of how Bioclinica continues to invest and innovate. “We’re pleased to deliver solutions in more areas of clinical development than any other technology provider, enabling organizations to see more clearly in their clinical research ─ and where it makes a real difference.” Deployment is fast and easy on all new studies where Bioclinica’s Express EDC and Data Management solution are in use, requiring little time and effort to learn and use effectively. “All studies, no matter the size or therapeutic area, can benefit from Clean Patient Optics,” Masters adds. Learn more online about Clean Patient Optics and Bioclinica Express, and read the Bioclinica blog and latest news on Bioclinica LinkedIn and Twitter channels. Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging & Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Randomization & Trial Supply Management; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.


News Article | May 29, 2017
Site: www.prnewswire.com

NEW YORK, May 29, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Contract Research Outsourcing in US$ Million by the following Service Segments: Drug Discovery, Preclinical Research, and Clinical Research. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Read the full report: http://www.reportlinker.com/p04910444/Global-Contract-Research-Outsourcing-Services.html Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 115 companies including many key and niche players such as - Albany Molecular Research, Inc. - Charles River Laboratories International, Inc. - Chiltern International Ltd. - ICON plc Read the full report: http://www.reportlinker.com/p04910444/Global-Contract-Research-Outsourcing-Services.html I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW Outsourcing of R&D Projects to Propel CROs Services Market Growth Drivers in a Nutshell Evolving Macro Trends Driving CRO Demand CROs to Significantly Drive Outsourcing Penetration Focus on Efficient, Quality Services to Drive Specialty CROs Market Rise in Investments to Boost Growth Key Therapeutic Areas of Clinical Trial Research Table 1: Global Clinical Trial Services Market by Therapeutic Area: 2016 (includes corresponding Graph/Chart) Primary Factors Influencing CRO Market Pharma and Biotech Companies to Increase Dependence on CROs Outlook Notable Regional Developments Future Model of CRO 2. COMPETITIVE SCENARIO CRO - A Highly Fragmented Market Table 2: Leading Players in the Global Contract Research Outsourcing Market (2016E): Percentage Breakdown of Revenues by Player (includes corresponding Graph/Chart) Table 3: Percentage Breakup of Life Sciences Revenues (2016) of Major Players by Service Type- Preclinical, Phase I, Phase IIA, Phase IIB, Phase III, Phase IV/ Post-Approval, Central Lab and Others Large CROs Seek the Inorganic Growth Route Global CRO Marketspace - A Review of the M&A Activity in the Recent Years Select M&A Activity in the Global CRO Market Noteworthy Contracts of Major CROs CROs Adept with New Technologies to See More Business in Future Streamlining Development of Novel Trial Designs CROs with End-to End Capabilities in Demand Key Opportunities for CROs Technological Superiority - A Definite Advantage Strategies and Tactical Programs for CROs Survival Strategies in Mature CRO Markets Exit from the Industry Expand Scale Capture Niche Segments Strategies to Tap Opportunities in Growing Markets Mobilize Funds Expand Other Services Upgrade Technological and Knowledge Base Form Sub-Contracts or Regional Alliances 3. GROWTH DRIVERS, MARKET TRENDS & ISSUES Increased Spend on R&D Outsourcing Table 4: Global Pharmaceutical R&D Spending (US$ Billion) for the Years 2010 through 2017 (includes corresponding Graph/Chart) Table 5: Percentage Breakdown of Total Number of Compounds in Pipeline by Phase for Pre-Clinical, Phase I, Phase II and Phase III: 2016E (includes corresponding Graph/Chart) Enhancing Site Selection and Patient Enrollment CROs Enter into Alliances to Improve Efficiencies Adoption of Digital Technologies Gains Pace Rising Late-Stage Services Demand and Budget Restraints Drive Market Growth Toxicology Services Gain Notable Attention Pharma Companies Enter into Licensing Agreements with Biotech Companies for New Drug Discovery - A Mutually Beneficial Strategy Pharmaceutical & Biopharmaceutical Trends to Support CRO Penetration Table 6: Global Biopharma % R&D Outsourcing (2014-2020) (includes corresponding Graph/Chart) Table 7: New FDA Drug Approvals (2010-2016): Breakdown of Number of Approvals by Type for New Molecular Entity (NME) and Biologic License Application (BLA) Approvals (includes corresponding Graph/Chart) Focus on Regulatory Oversight and Enhanced Transparency Bodes Well for CROs eClinical Solutions Gain Traction Other Noteworthy Market Trends CROs Monetize Data Service Differentiation - A Sustaining Strategy CROs Tie Up with Diagnostic Companies for Patients Research Networks Move to Cloud Application of Mobile Devices to Collect Real Time Data Gains Ground CROs Provide Exclusive Offers to Lure Big Pharma Challenges Faced by Contract Research Organizations On-shore versus Offshore CRO Business Cutthroat Competition among CROs Management of Clinical Investigation Cost Containment Safety Concerns on Clinical Trials Pipeline Blocks Surging Global Population Offers Increased Growth Opportunities Table 8: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (In Million) (includes corresponding Graph/Chart) Aging Population Boosts Opportunities for CRO Table 9: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart) Table 10: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart) Increasing Healthcare Expenditure to Spur Demand for Generics Table 11: Healthcare Spending as a Percentage of GDP by Region (2016E) (includes corresponding Graph/Chart) 4. CONTRACT RESEARCH OUTSOURCING - AN INSIGHT Concept Contract Research Organizations (CRO) Contract Research Outsourcing Major CRO Services Ancillary CRO Services Advantages from CRO Drug Discovery Pre-Clinical Studies Clinical Research - Factors Encouraging CRO Services at Various Phases Phase I Phase II Phase III Phase IV 5. RECENT INDUSTRY ACTIVITY WuXi AppTec Takes Over HD Biosciences Laboratory Corporation of America Holdings to Acquire Pharmaceutical Product Development PRA Health Sciences and Takeda Pharmaceutical Inks New Partnership AMRI Enters into Alliance with Bruker Daltonics and HighRes Biosolutions Pharmaceutical Product Development Establishes Rare Disease and Pediatric Center of Excellence Pharmaceutical Product Development to Start Clinical Research Unit in Las Vegas Bracket Acquires CLINapps PAREXEL International to Acquire ExecuPharm Cinven to Takeover BioClinica ICON to Takeover Clinical Research Management Pharmaceutical Product Development Acquires Evidera Velocity Fund Partners Acquires Indipharm Bioclinica Snaps Up Compass Research Charles River Laboratories International Takes Over Agilux Laboratories Charles River Laboratories International Snaps Up Blue Stream Laboratories Charles River Laboratories International Acquires WIL Research Pharmaron Announces the Acquisition of Quotient Bioresearch Amulet Capital Partners Acquires SynteractHCR Holdings IMS Health Merges with Quintiles Almac Clinical Technologies Enters into Partnership with inVentiv Health CSSi LifeSciences Unveils Fully Integrated Medical Device CRO Lovelace Biomedical Commences Operations as Preclinical CRO PAREXEL International Inks Services Agreement with Pfizer BioDuro Commences Operations as a Contract Research and Manufacturing Firm Charles River Laboratories International Forms Partnership with BioMotiv Laboratory Corporation of America Acquires Covance Charles River Laboratories International Snaps Up Oncotest Chiltern Acquires Theorem Clinical Research Charles River Laboratories International Takes Over Celsis International Albany Molecular Research Unveils Integrated Drug Discovery Center 6. FOCUS ON SELECT GLOBAL PLAYERS Albany Molecular Research, Inc. (USA) Charles River Laboratories International, Inc. (USA) Chiltern International Ltd. (UK) ICON plc (Ireland) INC Research, LLC (USA) InVentiv Health, Inc. (USA) Jubilant Biosys Ltd. (India) Laboratory Corporation of America® Holdings (USA) PAREXEL International Corp. (USA) Pharmaceutical Product Development, LLC. (USA) Pharmaron (China) PRA Health Sciences, Inc. (USA) Quintiles IMS Holdings, Inc. (USA) Ricerca Biosciences LLC (USA) Sygnature Discovery Limited (UK) SynteractHCR (USA) WuXi AppTec (China) 7. GLOBAL MARKET PERSPECTIVE Table 12: World Recent Past, Current & Future Analysis for Contract Research Outsourcing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 13: World Historic Review for Contract Research Outsourcing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 14: World 14-Year Perspective for Contract Research Outsourcing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) Table 15: World Recent Past, Current & Future Analysis for Contract Research Outsourcing for Drug Discovery by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 16: World Historic Review for Contract Research Outsourcing for Drug Discovery by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 17: World 14-Year Perspective for Contract Research Outsourcing for Drug Discovery by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) Table 18: World Recent Past, Current & Future Analysis for Contract Research Outsourcing for Preclinical Research by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 19: World Historic Review for Contract Research Outsourcing for Preclinical Research by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 20: World 14-Year Perspective for Contract Research Outsourcing for Preclinical Research by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) Table 21: World Recent Past, Current & Future Analysis for Contract Research Outsourcing for Clinical Research by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 22: World Historic Review for Contract Research Outsourcing for Clinical Research by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 23: World 14-Year Perspective for Contract Research Outsourcing for Clinical Research by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) III. MARKET 1. THE UNITED STATES A.Market Analysis Outlook Drug Developers Rely on CROs to Improve Trial Efficiency and Cost Savings Trial Services Witness Higher Demand Strong Demand for Data Management Services Focus on Innovation and Productivity CROs Focus on Adaptive Clinical Trials Risk-based Monitoring Catches Pace Strategic Corporate Developments Key Players B.Market Analytics Table 24: US Recent Past, Current & Future Analysis for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 25: US Historic Review for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 26: US 14-Year Perspective for Contract Research Outsourcing by Service Type - Percentage Breakdown of Revenues for Drug Discovery, Preclinical Research and Clinical Research Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) 2. CANADA Market Analysis Table 27: Canadian Recent Past, Current & Future Analysis for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 28: Canadian Historic Review for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 29: Canadian 14-Year Perspective for Contract Research Outsourcing by Service Type - Percentage Breakdown of Revenues for Drug Discovery, Preclinical Research and Clinical Research Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) 3. JAPAN A.Market Analysis Strategic Corporate Development B.Market Analytics Table 30: Japanese Recent Past, Current & Future Analysis for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 31: Japanese Historic Review for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 32: Japanese 14-Year Perspective for Contract Research Outsourcing by Service Type - Percentage Breakdown of Revenues for Drug Discovery, Preclinical Research and Clinical Research Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) 4. EUROPE A.Market Analysis Outlook Providers Expand Services in Downstream Drug Development Strategic corporate developments Key Players B.Market Analytics Table 33: European Recent Past, Current & Future Analysis for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 34: European Historic Review for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 35: European 14-Year Perspective for Contract Research Outsourcing by Service Type - Percentage Breakdown of Revenues for Drug Discovery, Preclinical Research and Clinical Research Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) 5. ASIA-PACIFIC A.Market Analysis Outlook Asia-Pacific to Push up Volume Share in CRO Market R&D Outsourcing in Life Sciences on Rise Focus on Select Regional Markets China Market with Strong Growth Potential India Australia Popular Destination for Early Phase Clinical Trials Cost Savings through Tax Incentives Supportive Regulatory Framework Government Focus on Reducing Cost and Time Superior Clinical Trial Quality Strategic Corporate Development Key Players B.Market Analytics Table 36: Asia-Pacific Recent Past, Current & Future Analysis for Contract Research Outsourcing by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 37: Asia-Pacific Historic Review for Contract Research Outsourcing by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 38: Asia-Pacific 14-Year Perspective for Contract Research Outsourcing by Geographic Region - Percentage Breakdown of Revenues for China, India and Rest of Asia-Pacific Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) Table 39: Asia-Pacific Recent Past, Current & Future Analysis for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 40: Asia-Pacific Historic Review for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 41: Asia-Pacific 14-Year Perspective for Contract Research Outsourcing by Service Type - Percentage Breakdown of Revenues for Drug Discovery, Preclinical Research and Clinical Research Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) 6. REST OF WORLD A.Market Analysis Outlook Providers with Specialized Research Techniques to Boost Latin American CRO Market B.Market Analytics Table 42: Rest of World Recent Past, Current & Future Analysis for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 43: Rest of World Historic Review for Contract Research Outsourcing by Service Type - Drug Discovery, Preclinical Research and Clinical Research Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 44: Rest of World 14-Year Perspective for Contract Research Outsourcing by Service Type - Percentage Breakdown of Revenues for Drug Discovery, Preclinical Research and Clinical Research Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 115 (including Divisions/Subsidiaries - 120) The United States (47) Canada (5) Japan (1) Europe (27) - France (2) - Germany (6) - The United Kingdom (3) - Spain (1) - Rest of Europe (15) Asia-Pacific (Excluding Japan) (35) Latin America (4) Read the full report: http://www.reportlinker.com/p04910444/Global-Contract-Research-Outsourcing-Services.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-contract-research-outsourcing---services-300465052.html

Loading BioClinica collaborators
Loading BioClinica collaborators